2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4130 CD4+ car-T cells eliminate tumors through mitochondria-associated inflammatory components transfer to induce caspase-8-dependent immunogenic cell death

Yixin Wang, Huajian Xian III2, Chaoqun Lu3, Wenjing Shu, PhD4, Zixuan Huang5, Xiaoli Xia6, Dan Li7, Han Liu8
1 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
2 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
3 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
4 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
5 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
6 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
7 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
8 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China

Background: Chimeric antigen receptor T (CAR-T) cell therapies have shown remarkable efficacy in B cell leukemia and multiple myeloma. However, durable responses remain limited by heterogeneous tumor-cell susceptibility, incomplete elimination of malignant cells, and antigen escape. CD4+ CAR-T cells have attracted growing attention in recent years due to their dual roles in modulating the immune microenvironment and killing tumor cells, but the direct cytotoxic mechanism intrinsic for CD4+ CAR-T cells still remain incompletely understood. Defining killing pathways employed by CD4+ CAR-T cells may provide new strategies to improve CAR-T efficacy and overcome therapeutic resistance.

Methods:
To investigate CD4+ CAR-T-mediated tumor killing, purified CD4+ CAR-T cells were co-cultured with tumor cells, and cytotoxicity and antigen expression were evaluated in vitro, with antitumor efficacy further assessed in vivo. Extracellular vesicles (EVs) populations released from CD3/CD28 bead-stimulated CD4+ CAR-T cells were isolated by ultracentrifugation and ultrafiltration. EV-mediated mechanisms were examined using transwell assays, RNA sequencing, CRISPR-Cas9, immunofluorescence and mouse models. Lysosomal inhibition was used to assess whether modulation of EV trafficking could enhance CD4+ CAR-T activity against resistant tumors.

Results:
CD4+ CAR-T cells eliminate tumor cells through an underappreciated low-density extracellular vesicle (LD-EV) associated with antigen depletion that distinct from classical CTL-mediated killing, which relies primarily on direct cell-cell contact. The proteomic analysis and immunoblotting of LD-EVs revealed that, unlike previously described CAR-T-derived EV populations enriched in perforin and granzymes, LD-EVs carry mitochondria-associated inflammatory components. Following uptake by tumor cells, LD-EVs induce reactive oxygen species (ROS) accumulation, triggering an inflammatory signaling cascade that culminates in activation of a caspase-8-dependent immunogenic cell death (ICD) program.
Mechanistically, inhibition of classical cytotoxic pathways, including knockout perforin/granzyme, demonstrated that CD4+ CAR-T-mediated killing is largely independent of canonical CTL effectors. In contrast, genetic deletion of caspase-8 in tumor cells substantially reduced LD-EV-mediated cytotoxicity, demonstrating that tumor-cell intrinsic caspase-8 activation is required for this inflammatory cell death pathway. Furthermore, CRISPR/Cas9-mediated disruption of NLRP3/TXNIP signaling in CD4+ CAR-T cells impaired LD-EV-mediated tumor killing, establishing the importance of an inflammatory signaling module in regulating LD-EV function.
Beyond defining this mechanism, we found that LD-EV intracellular trafficking determines divergent tumor-cell outcomes. Tumor cells with productive LD-EV-mediated inflammatory signaling undergo elimination, whereas insensitive tumor cells preferentially redirect LD-EVs toward lysosomal degradation, limiting inflammatory signaling and enabling survival despite antigen depletion. Notably, lysosomal inhibition redirected intracellular trafficking and restored CD4+ CAR-T-mediated killing in resistant tumor models.

Conclusion:
Our study reveals a previously unrecognized contact-independent cytotoxic mechanism by which CD4+ CAR-T cells directly eliminate tumor cells through LD-EV-mediated transfer of mitochondria-associated inflammatory components. By establishing LD-EVs as specialized mediators of caspase-8-dependent ICD, this study expands current understanding of CAR-T biology beyond classical cytotoxic lymphocyte pathways and provides mechanistic insights into heterogeneous tumor responses, antigen evolution, and therapeutic resistance. Targeting LD-EV generation or intracellular trafficking may represent a strategy to enhance durable CAR-T responses.

Yixin Wang: No relevant conflicts of interest to declare.